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Urothelial bladder cancer (UBC) is burdensome for patients and expensive for healthcare 20 
providers [1]. Outcomes have changed little for three decades, despite significant 21 
improvements in 5-year survival rates for prostate and kidney cancers during this period [1]. 22 
Furthermore, patient pathways are complex, prolonged, and practiced in various permutations 23 
at every stage:  24 
• The investigation of patients with suspected UBC requires multiple diagnostic 25 
procedures [2;3]; various combinations of tests are utilised [4]. 26 
• TURBT can performed by a number of different techniques with a number of different 27 
energy sources, and utilising a variety of optical image enhancement technologies [5].  28 
• Further treatment may be required in the form of intravesical therapy with various 29 
agents, with or without chemohyperthermia or electromotive drug administration [3]. 30 
• Long-term surveillance is the mainstay of subsequent management [2;3]; various 31 
surveillance schedules are practiced [6].  32 
• Surveillance may or may not utilize urinary biomarkers, and treatment of recurrence 33 
may be carried out in the office or the operating theatre [6].  34 
• For curative intent, patients who present with or progress to MIBC are treated by 35 
radiotherapy [2;7], chemoradiotherapy [8], radical cystectomy (open, laparoscopic or 36 
robot-assisted), or neoadjuvant chemotherapy followed by radical cystectomy [2;7]; 37 
adjuvant chemotherapy is utilized in some units.  38 
 39 
In this month’s issue of European Urology, Svatek et al provide a review of the costs and other 40 
considerations for these approaches, and discuss key issues regarding the wider economics of 41 
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bladder cancer care [6]. This represents a useful overview for the practicing urologist. In 42 
particular, the authors demonstrate that there are large gaps in our knowledge regarding the 43 
efficacy and cost-effectiveness of these approaches and a lack of sufficiently-powered 44 
randomised controlled trials (RCTs), with expensive tools having crept into everyday practice 45 
without the necessary thorough evaluations. They highlight that there is a clear and urgent 46 
need for the development of new drugs for UBC, both NMIBC and MIBC. The prevalence of 47 
NMIBC and its protracted course compared to MIBC is such that the cumulative cost of care is 48 
thought to be even more substantial than MIBC [6], so the gains to be made in preventing 49 
recurrence and progression of NMIBC could be the most significant. Furthermore, the individual 50 
physician has the greatest impact on the cost of care of NMIBC, yet variation in treatment 51 
intensity does not impact survival or the avoidance of subsequent major interventions [6]. 52 
Other authors have recently highlighted these and other issues in bladder cancer care [1]. 53 
However, in order to make practice-changing recommendations, robust and detailed 54 
assessments of specific elements of these complicated pathways are required, utilizing complex 55 
modeling and statistics, and measures of cost-effectiveness. Such analyses have previously 56 
been undertaken in the UK in the form of Health Technology Assessments [4;9]. Reasonably, 57 
Svatek et al do not venture into this complex territory, but such health services research is 58 
urgently needed alongside basic and translational research and clinical trials [1]. Furthermore, 59 
the non-medical costs associated with UBC care (that are borne by patients, their families, their 60 
employers) and the costs associated with untimely deaths due to UBC are simply staggering [6]. 61 
Perhaps the treatment of UBC has far more impact on HRQoL than we have previously realised? 62 
 63 
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The Authors could have been more prescriptive in their conclusions to send a clearer message. 64 
For example, they present data that level 1 evidence and clinical guidelines are being ignored 65 
[1;6], yet fail to recommend that such evidence and guidelines be more closely adhered to. 66 
Perhaps we don’t actually need more RCTs of BCG maintenance therapy, which are both 67 
expensive and protracted? Instead, would a better use of resources be to gain a clearer 68 
understanding of BCG’s mechanism of action and the immunological milieu of the bladder 69 
tumour microenvironment, potentially leading to the development of new therapeutics for all 70 
UBC patients? NMIBC is also an ideal setting in which to assess the effectiveness of novel low 71 
toxicity therapeutics and/or chemopreventive agents administered long-term (and several such 72 
RCTs are in follow-up, eg. BOXIT, SELENIB), yet such strategies are not discussed by the Authors. 73 
As for urinary biomarkers, their real utility may not actually lie in their ability to detect new or 74 
recurrent disease, but in their ability to risk stratify patients early in their pathway so that they 75 
are investigated and managed more appropriately and expeditiously [10]. There is a lot that we 76 
could do now to redesign these pathways and interventions [10], yet there is a reluctance to 77 
change and a significant lack of research funding [1]. 78 
And it is this lack of research funding that underlies our complex and varied pathways. We don’t 79 
actually have the robust evidence base to support a lot of what we do, and where the robust 80 
evidence and high grade recommendations exist, the uptake is poor (eg. single-shot intravesical 81 
mitomycin C [3], neoadjuvant platinum-based combination chemotherapy [7]) [6]. 82 
Consequently, a spectrum of alternatives is practiced by individual urologists and/or individual 83 
units, possibly accentuated in the USA by illogical reimbursement patterns [1]. The Authors’ 84 
lack of decisive conclusions is therefore understandable.  85 
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If we are to tackle bladder cancer and improve outcomes, as we have done for prostate and 86 
kidney cancer, then we need to lobby for more funding for RCTs, translational science and 87 
health services research, and address the poor awareness of UBC among the general public and 88 
the nonurological scientific community [1]. And where are MIBC’s innovative new drugs? It 89 
feels as though the pharmaceutical industry have deserted UBC in search of lower hanging fruit. 90 
These issues were specifically discussed amongst leading UK urologists and oncologists at The 91 
Royal Society of Medicine Section of Urology Annual Winter Meeting in January, and it was 92 
concluded that The Royal Society of Medicine, the British Association of Urological Surgeons, 93 
The Urology Foundation and Action on Bladder Cancer should endeavour to undertake a 94 
collaborative and concerted effort to advance the cause for bladder cancer patients. We need 95 
to make much more progress, perhaps improving cost-effectiveness along the way. 96 
97 
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